Foresite Capital Management III’s Solid Biosciences SLDB Stock Holding History

Foresite Capital Management III’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-6,596	Closed	-$2.65M	–	21
2018 Q4	$2.65M	Sell	6,596 -9,263	-58%	-$4.35M	0.87%	18
2018 Q3	$11.2M	Sell	15,859 -6,667	-30%	-$4.19M	2.48%	13
2018 Q2	$12M	Hold	22,526	–	–	2.59%	14
2018 Q1	$2.02M	Buy	+22,526	New	+$7.61M	0.44%	20

Other funds holding SLDB

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Foresite Capital Management III's SLDB Position: Q1 2019 in Review

Foresite Capital Management III sold out of Solid Biosciences (SLDB) in Q1 2019, closing a stake of 6,596 shares — an estimated $2.65M sold.

Foresite Capital Management III first reported a position in SLDB in Q1 2018 and held it in 4 quarters. The position peaked at $12M in Q2 2018. 74 funds tracked by Wall St. Rank hold SLDB as of Q1 2019.

Foresite Capital Management III reported no remaining Solid Biosciences position as of Q1 2019 after selling out during the quarter.
Foresite Capital Management III sold 6,596 Solid Biosciences shares in Q1 2019, an estimated $2.65M.
Foresite Capital Management III first reported a position in Solid Biosciences in Q1 2018 and held it in 4 quarters.
Foresite Capital Management III's Solid Biosciences position peaked at $12M in Q2 2018.
74 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2019.

Based on Foresite Capital Management III's 13F filing for Q1 2019, filed 14 May 2019.